Abstract
Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.
| Original language | English |
|---|---|
| Pages (from-to) | 453-459 |
| Number of pages | 7 |
| Journal | Clinical Endocrinology |
| Volume | 65 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2006 Oct 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
}
The long-term effects of rosiglitazone on serum lipid concentrations and body weight. / Shim, Wan Sub; Do, Mi Young; Kim, Soo Kyung; Kim, Hae Jin; Hur, Kyu Yeon; Kang, Eun Seok; Ahn, Chul Woo; Lim, Sung Kil; Lee, Hyun Chul; Cha, Bong Soo.
In: Clinical Endocrinology, Vol. 65, No. 4, 01.10.2006, p. 453-459.Research output: Contribution to journal › Article
TY - JOUR
T1 - The long-term effects of rosiglitazone on serum lipid concentrations and body weight
AU - Shim, Wan Sub
AU - Do, Mi Young
AU - Kim, Soo Kyung
AU - Kim, Hae Jin
AU - Hur, Kyu Yeon
AU - Kang, Eun Seok
AU - Ahn, Chul Woo
AU - Lim, Sung Kil
AU - Lee, Hyun Chul
AU - Cha, Bong Soo
PY - 2006/10/1
Y1 - 2006/10/1
N2 - Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.
AB - Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.
UR - http://www.scopus.com/inward/record.url?scp=33748767108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748767108&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.2006.02614.x
DO - 10.1111/j.1365-2265.2006.02614.x
M3 - Article
C2 - 16984237
AN - SCOPUS:33748767108
VL - 65
SP - 453
EP - 459
JO - Clinical Endocrinology
JF - Clinical Endocrinology
SN - 0300-0664
IS - 4
ER -